Tenaya Therapeutics, Inc. Financing Cash Flow
Tenaya Therapeutics, Inc. (TNYA) reported Financing Cash Flow of $494.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-05
- Tenaya Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $909.00K.
- Tenaya Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was -$415.00K, a 100.83% decline year-over-year.
- Tenaya Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $58.24M, a 15348.81% increase year-over-year.
- Tenaya Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $380.00K, a 1125.81% increase year-over-year.
- Tenaya Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $108.41M, a 127.03% increase from fiscal 2024.
- Tenaya Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $47.75M, a 1079.28% increase from fiscal 2023.
- Tenaya Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $4.05M, a 94.79% decline from fiscal 2022.
- Tenaya Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2022 was $77.77M, a 62.79% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $909.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $494.00K 10-Q · filed 2026-08-05 | $58.74M derived: sum of 3 quarters · filed 2026-08-05 | $59.12M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$415.00K 10-Q · filed 2026-05-06 | $57.83M derived: sum of 2 quarters · filed 2026-05-06 | $58.21M derived: sum of 3 quarters · filed 2026-05-06 | $57.73M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $58.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $58.62M derived: sum of 2 quarters · filed 2026-03-11 | $58.15M derived: sum of 3 quarters · filed 2026-08-05 | $108.41M 10-K · filed 2026-03-11 |
| 2025-09-30 | $380.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$96.00K derived: sum of 2 quarters · filed 2026-08-05 | $50.16M 10-Q · filed 2025-11-10 | $50.54M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$476.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $49.78M 10-Q · filed 2026-08-05 | $50.16M derived: sum of 3 quarters · filed 2026-08-05 | $50.19M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $50.26M 10-Q · filed 2026-05-06 | $50.64M derived: sum of 2 quarters · filed 2026-05-06 | $50.67M derived: sum of 3 quarters · filed 2026-05-06 | $51.24M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $377.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $408.00K derived: sum of 2 quarters · filed 2026-03-11 | $978.00K derived: sum of 3 quarters · filed 2026-03-11 | $47.75M 10-K · filed 2026-03-11 |
| 2024-09-30 | $31.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $601.00K derived: sum of 2 quarters · filed 2025-11-10 | $47.37M 10-Q · filed 2025-11-10 | $47.74M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $570.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $47.34M 10-Q · filed 2025-08-06 | $47.71M derived: sum of 3 quarters · filed 2025-08-06 | $47.71M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $46.77M 10-Q · filed 2025-05-07 | $47.14M derived: sum of 2 quarters · filed 2025-05-07 | $47.14M derived: sum of 3 quarters · filed 2025-05-07 | $51.32M derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | $371.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $371.00K derived: sum of 2 quarters · filed 2025-03-10 | $4.55M derived: sum of 3 quarters · filed 2025-03-10 | $4.05M 10-K · filed 2025-03-10 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $4.18M derived: sum of 2 quarters · filed 2024-11-06 | $3.68M 10-Q · filed 2024-11-06 | $81.16M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $4.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $3.68M 10-Q · filed 2024-08-08 | $81.16M derived: sum of 3 quarters · filed 2024-08-08 | $81.17M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$501.00K 10-Q · filed 2024-05-14 | $76.98M derived: sum of 2 quarters · filed 2024-05-14 | $76.99M derived: sum of 3 quarters · filed 2024-05-14 | $77.25M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $77.49M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | $77.49M derived: sum of 2 quarters · filed 2024-03-18 | $77.75M derived: sum of 3 quarters · filed 2024-03-18 | $77.77M 10-K · filed 2024-03-18 |
| 2022-09-30 | $6.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $266.00K derived: sum of 2 quarters · filed 2023-11-08 | $281.00K 10-Q · filed 2023-11-08 | $260.00K derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $260.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $275.00K 10-Q · filed 2023-08-09 | $254.00K derived: sum of 3 quarters · filed 2023-08-09 | $190.53M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $15.00K 10-Q · filed 2023-05-10 | -$6.00K derived: sum of 2 quarters · filed 2023-05-10 | $190.27M derived: sum of 3 quarters · filed 2023-05-10 | $188.97M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | -$21.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | $190.25M derived: sum of 2 quarters · filed 2023-03-08 | $188.96M derived: sum of 3 quarters · filed 2023-03-08 | $208.97M 10-K · filed 2023-03-08 |
| 2021-09-30 | $190.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $188.98M derived: sum of 2 quarters · filed 2022-11-10 | $208.99M 10-Q · filed 2022-11-10 | $294.92M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$1.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $18.72M 10-Q · filed 2022-08-10 | $104.64M derived: sum of 3 quarters · filed 2022-08-10 | $135.34M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $20.02M 10-Q · filed 2022-05-11 | $105.94M derived: sum of 2 quarters · filed 2022-05-11 | $136.63M derived: sum of 3 quarters · filed 2022-05-11 | |
| 2020-12-31 | $85.92M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-23 | $116.62M derived: sum of 2 quarters · filed 2022-03-23 | $147.27M 10-K · filed 2022-03-23 | |
| 2020-09-30 | $30.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $61.34M 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | $30.65M 10-Q · filed 2021-09-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |